Status:
TERMINATED
Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database
Lead Sponsor:
Emory University
Collaborating Sponsors:
The Leukemia and Lymphoma Society
Conditions:
Leukemia, Promyelocytic, Acute
Eligibility:
All Genders
Brief Summary
Acute promyelocytic leukemia (APL) is a very rare type of leukemia. Because it is so rare, many doctors do not have experience treating it. APL has been shown to be curable most of the time. Unfortuna...
Detailed Description
The investigators propose to collect data on patients with APL treated predominantly across the states of Georgia and South Carolina but will also extend it to cover patients from neighboring states. ...
Eligibility Criteria
Inclusion
- Confirmed diagnosis of APL
- Positive t (15:17) by fluorescence in situ hybridization (FISH)
- Promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha by polymerase chain reaction (PCR)
Exclusion
- Only patients who refuse to provide consent will be excluded from the study
Key Trial Info
Start Date :
November 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2018
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT02309333
Start Date
November 1 2014
End Date
September 1 2018
Last Update
December 10 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Emory University Winship Cancer Institute
Atlanta, Georgia, United States, 30322
2
Northside Hospital
Atlanta, Georgia, United States, 30342
3
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
4
Gibbs Cancer Center and Research Institute
Spartanburg, South Carolina, United States, 29303